Effects of Evolocumab on Cardiovascular Events

BACKGROUND: Evolocumab is a potent lipid-lowering drug that decreases plasma levels of low-density lipoprotein cholesterol (LDL-C) by 50-60%. FOURIER is a landmark randomized trial involving 27,564 patients with established cardiovascular disease already on statins and plasma LDL-C levels > 70 mg...

Descripción completa

Detalles Bibliográficos
Autor principal: Mikhail, Nasser
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730965/
https://www.ncbi.nlm.nih.gov/pubmed/28925859
http://dx.doi.org/10.2174/1573403X13666170918165713

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730965/
https://www.ncbi.nlm.nih.gov/pubmed/28925859
http://dx.doi.org/10.2174/1573403X13666170918165713

Ejemplares similares